Alzheimer’s drug safety

EU Rejects Alzheimer's Drug from Eisai and Biogen

Shocking Decision By EMA As It Rejects Alzheimer’s Drug from Eisai and Biogen

by Megan Wood
July 30, 2024July 30, 2024

The European Medicines Agency has rejected the Alzheimer’s drug from Eisai and Biogen due to safety concerns. Learn more about the implications for Alzheimer’s treatment.